# US 2026/0131020 A1 · Ionizable cationic lipid for rna delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0131020 A1
- Document ID: US20260131020A1
- Status: Published application
- Kind: A1
- Application number: 19/430,636
- Filed: 2025-12-23
- Published: 2026-05-14
- Earliest claimed: 2016-12-21
- Assignees: Arcturus Therapeutics, Inc.
- Applicants: Arcturus Therapeutics, Inc.
- Inventors: Joseph E. Payne; Padmanabh Chivukula; Priya Karmali; Steven P. Tanis
- Web page: https://patentgrep.com/patent/US20260131020A1

## CPC

- A61K 48/0025: {wherein the non-active part clearly interacts with the delivered nucleic acid}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- C07C 333/04: having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

What is described is a compound of formula I consisting of a compound in which R1 is a branched chain alkyl consisting of 10 to 31 carbons; R2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons; L1 and L2 are the same or different, each a linear alkylene or alkenylene consisting of 2 to 20 carbons; X1 is S or O; R3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A compound of formula I
wherein
R1 is a branched chain alkyl consisting of 10 to 31 carbons,
R2 is a linear alkyl, alkenyl or alkynyl consisting of 2 to 20 carbons,
R3 is a linear or branched alkylene consisting of 1 to 6 carbons,
R4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons;
L1 and L2 are the same or different, each a linear alkylene or alkenylene consisting of 1 to 20 carbons, and
X1 is S or O;
or a salt or solvate thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein X1 consists of S.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R3 consists of ethylene or propylene.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R4 and R5 separately are methyl or ethyl.

### Claim 5 (depends on 1)

The compound of claim 1, wherein L2 is C1, C3, or C5.

### Claim 6 (depends on 5)

The compound of claim 5, wherein L1 is C1, C2, C3, or C5.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R2 is an alkenyl.

### Claim 8 (depends on 7)

The compound of claim 7 wherein R2 is a C9 alkenyl.

### Claim 9 (depends on 7)

The compound of claim 7, wherein R1 consists of —CH((CH2)nCH3)2, wherein n is 4, 5, 6, or 7.

### Claim 10 (depends on 9)

The compound of claim 9, wherein n is 5 and L1 is C1 or C3.

### Claim 11 (depends on 9)

The compound of claim 9, wherein n is 6 and L1 is C3 or C5.

### Claim 12 (depends on 9)

The compound of claim 9, wherein n is 7 and L1 is C1, C2, or C3.

### Claim 13 (depends on 9)

The compound of claim 9, wherein n is 8 and L1 is C1 or C3.

### Claim 14 (depends on 7)

The compound of claim 7, wherein R1 consists of —CH((CH2)nCH3)((CH2)n+1CH3), wherein n is 6 or 7.

### Claim 15 (depends on 1)

The compound of claim 1, selected from the group consisting of a compound of formula ATX-43, ATX-57, ATX-58, ATX-61, ATX-63, ATX-64, ATX-81, ATX-82, ATX-83, ATX-84, ATX-86, ATX-87, and ATX-88.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1.

### Claim 17 (depends on 1)

The pharmaceutical composition of claim 1, comprising the compound of claim 1 in a lipid nanoparticle.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17, wherein the lipid nanoparticle further comprises a neutral lipid and a conjugated lipid.

### Claim 19 (depends on 17)

The pharmaceutical composition of claim 17, wherein the lipid nanoparticle encapsulates mRNA.

### Claim 20 (depends on 17)

The pharmaceutical composition of claim 17, further comprising mRNA encoding a biologically active protein.

### Claim 21 (depends on 17)

The pharmaceutical composition of claim 17, further comprising RNA comprising a nucleotide sequence homologous to a mRNA in a target cell.
